Difelikefalin Impurity 19 is a difelikefalin-related peptide used to profile side products and decomposition pathways. Its sequence deviates subtly from the main active backbone, altering polarity and conformational preferences. Researchers use it to challenge analytical resolution and structural-assignment robustness. Applications include stability-indicating method development, impurity mapping, and structure-property investigation.
CAT No: Z10-101-200
Synonyms/Alias:1-(L-leucyl-L-lysyl)-4-aminopiperidine-4-carboxylic acid
Difelikefalin Impurity 19 is a synthetic peptide derivative that serves as a structurally related analogue to the main active pharmaceutical ingredient, difelikefalin. As a peptide impurity, it is of significant interest within the context of peptide synthesis, pharmaceutical development, and analytical research. Its presence and characterization are essential for a comprehensive understanding of the chemical profile, purity, and quality of difelikefalin preparations. The unique structure of this impurity provides valuable insights into the synthetic process, degradation pathways, and potential byproducts associated with peptide-based drug manufacturing, making it a critical reference compound for research and quality control laboratories.
Analytical method development: Difelikefalin Impurity 19 is widely utilized as a reference standard in the development and validation of analytical methods for peptide drugs. Its inclusion in chromatographic and spectrometric assays enables researchers to accurately detect, identify, and quantify trace impurities within complex peptide formulations. By establishing robust analytical protocols that account for such impurities, laboratories can ensure the reliability, sensitivity, and specificity of their quality control processes, ultimately supporting consistent batch-to-batch reproducibility.
Impurity profiling and characterization: The compound plays a pivotal role in impurity profiling studies, where its precise identification and quantification help delineate the impurity landscape of difelikefalin and related peptides. Understanding the structural and chemical properties of Impurity 19 allows researchers to map degradation pathways, evaluate synthetic byproducts, and assess the impact of manufacturing variables on impurity formation. These insights are critical for risk assessment, regulatory submissions, and the overall safety evaluation of peptide-based drug candidates.
Process optimization in peptide synthesis: In peptide manufacturing, the occurrence of specific impurities such as Difelikefalin Impurity 19 provides valuable feedback regarding the efficiency and selectivity of synthetic routes. By monitoring its levels during process development, chemists can optimize reaction conditions, purification strategies, and reagent choices to minimize impurity formation. This targeted approach not only enhances the overall yield and purity of the desired peptide but also streamlines scale-up and technology transfer efforts in industrial settings.
Stability studies: The presence and behavior of Impurity 19 under various storage and stress conditions are integral to comprehensive stability testing of peptide products. By tracking its formation over time or under accelerated degradation scenarios, researchers can gain insights into the chemical robustness of difelikefalin formulations. Such data inform shelf-life determinations, packaging decisions, and storage recommendations, ensuring the long-term integrity of peptide therapeutics throughout their lifecycle.
Structure-activity relationship investigations: The structural similarity of Difelikefalin Impurity 19 to its parent compound makes it a valuable tool in structure-activity relationship (SAR) studies. By comparing the physicochemical and biological properties of the impurity with those of difelikefalin, scientists can elucidate the impact of specific molecular modifications on peptide behavior. These findings contribute to a deeper understanding of peptide structure, inform rational design of next-generation analogues, and support ongoing innovation in peptide drug discovery and development.
2. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die
4. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More